Table 3.

Summary of treatment regimen, local control, progression-free survival, overall survival and late toxicity in previous studies compared with the present study

Ref.	No. of patients	SBRT dose (Gy/No. of fractions)	Gemcitabine-based chemotherapy	LC (%)	PFS (mo)	OS (mo)	Toxicity (≥ G2) (%)
Didolkar et al[17]	85	15-30 Gy/3	Sequential	91.7	-	18.6 from diagnosis 8.6 from SBRT	22
Polistina et al[18]	23	30 Gy/3	Prior	82.6	7.3	10.6	None
Mahadevan et al[19]	39	24-36 Gy/3	Sequential	85	15	20 from diagnosis	9
Schellenberg et al[20]	16	25 Gy/1	Sequential	81	9	11.4 from diagnosis	47
Hoyer et al[21]	22	45 Gy/3	Sequential	57	4.8	5.7 from diagnosis	18
Koong et al[22]	15	15-25 Gy/1	No	77	2	11 from diagnosis	None
Chang et al[23]	77	25 Gy/1	Prior	84	-	11.4 from diagnosis	13
Schellenberg et al[24]	20	25 Gy/1	Sequential	94	9.2	11.8 from diagnosis	20
Rwigema et al[25]	71	18-25 Gy/1	No	64.8	-	10.3	10
Pollom et al[26]	167	25-33 Gy/1-5	Sequential or concurrent	-	-	13.6 from diagnosis	12.3
Moningi et al[27]	88	20-33 Gy/5	Gemcitabine, cisplatin, FOLFIRINOX or paclitaxel	-	9.8	18.4 from diagnosis	5.7 G23.4 G3
Gurka et al[28]	38	25-30 Gy/5	Gemcitabine, mFOLFOX or capecitabine	79	9.2	14.3 from diagnosis	-
Present study	25	30-36 Gy/3 or 42-48Gy/4	4 patients, Gemcitabine	-	-	M0 group 13.5 M1 group 8.5 from SBRT	4

LC: Local control; OS: Overall survival; PFS: Progression-free survival; SBRT: Stereotactic body radiotherapy.